Twist Bioscience Corporation (TWST) Stock Score, Valuation & Financial Research
Twist Bioscience Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for TWST
Twist Bioscience Corporation currently has a Wall Street Score of 22/100. The stored market price is $127.22. Its financial score is 44/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Twist Bioscience Corporation does
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the compa
TWST financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $127.22
- Market capitalization:
- $7.92B
- Revenue:
- $409.5M
- Net income:
- $-81.3M
- Free cash flow:
- $-75.6M
- Cash:
- $122.7M
- Total debt:
- $95.8M
- EPS:
- -1.30
- Financial score:
- 44/100
- Valuation score:
- 0/100
- Revenue score:
- 29/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-75.6M, showing cash burn in the current stored period.
- The balance sheet shows $122.7M of cash versus $95.8M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 44/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TWST
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.